Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltanexor - Karyopharm Therapeutics

Next Previous
Drug Profile

Eltanexor - Karyopharm Therapeutics

Alternative Names: ATG 016; KPT-8602; ONO-7706

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Antengene Corporation; Karyopharm Therapeutics; Rega Institute for Medical Research
  • Class Anti-inflammatories; Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Nasopharyngeal cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • No development reported Acute myeloid leukaemia; Gastric cancer; Inflammatory bowel diseases; Oesophageal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in Belgium (PO)
  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in Triple-negative-breast-cancer in Unknown (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top